Intraocular lymphoma
Conditions
Interventions
Perform intravitreal MTX (400 ug/100 ul) injection weekly for the eyes that were diagnosed as intraocular lymphoma until the lymphoma lesions are resolved.
Sponsors
Department of Ophthalmology & Visual Science, Tokyo Medical and Dental University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A. Patients of intraocular lymphoma diagnosed according to the following criteria: 1) positive for characteristic ocular symptoms and findings of lymphoma 2) pathologically diagnosed as lymphoma 3) positive for IgH gene clonality detected by PCR assay or flow cytometry 1 with 2 or 3 B. Patients whose written informed consent can be obtained.
Exclusion criteria
Exclusion criteria: (1) Eyes with severe intraocular infectious disease (2) History of serious adverse reactions by methotrexate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission of the intraocular lesions, visual acuity, cytokine levels in intraocular fluids, and recurrence rate in two years. | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of adverse events, and relapse rate (central nerve system and other lesion) | — |
Countries
Japan
Contacts
Public ContactHiroshi Takase
Tokyo Medical and Dental University Department of Ophthalmology & Visual Science
Outcome results
None listed